HomeCompareVNTA vs EQR

VNTA vs EQR: Dividend Comparison 2026

VNTA yields 4987.53% · EQR yields 4.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VNTA wins by $60726414423802.55M in total portfolio value
10 years
VNTA
VNTA
● Live price
4987.53%
Share price
$0.04
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$60726414423802.59M
Annual income
$58,422,163,401,288,310,000.00
Full VNTA calculator →
EQR
EQR
● Live price
4.73%
Share price
$58.58
Annual div
$2.77
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.5K
Annual income
$3,819.61
Full EQR calculator →

Portfolio growth — VNTA vs EQR

📍 VNTA pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVNTAEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VNTA + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VNTA pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VNTA
Annual income on $10K today (after 15% tax)
$423,940.15/yr
After 10yr DRIP, annual income (after tax)
$49,658,838,891,095,065,000.00/yr
EQR
Annual income on $10K today (after 15% tax)
$401.93/yr
After 10yr DRIP, annual income (after tax)
$3,246.67/yr
At 15% tax rate, VNTA beats the other by $49,658,838,891,095,065,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VNTA + EQR for your $10,000?

VNTA: 50%EQR: 50%
100% EQR50/50100% VNTA
Portfolio after 10yr
$30363207211901.31M
Annual income
$29,211,081,700,644,155,000.00/yr
Blended yield
96.21%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

VNTA
No analyst data
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+20.1% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VNTA buys
0
EQR buys
0
No recent congressional trades found for VNTA or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVNTAEQR
Forward yield4987.53%4.73%
Annual dividend / share$2.00$2.77
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$60726414423802.59M$40.5K
Annual income after 10y$58,422,163,401,288,310,000.00$3,819.61
Total dividends collected$60570499970588.68M$16.9K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: VNTA vs EQR ($10,000, DRIP)

YearVNTA PortfolioVNTA Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$509,453$498,753.12$11,248$547.57+$498.2KVNTA
2$24,291,968$23,746,853.30$12,701$666.53+$24.28MVNTA
3$1,084,224,114$1,058,231,708.37$14,405$814.59+$1084.21MVNTA
4$45,302,256,588$44,142,136,785.73$16,413$999.84+$45302.24MVNTA
5$1,772,207,810,855$1,723,734,396,305.83$18,795$1,232.92+$1772207.79MVNTA
6$64,916,695,091,411$63,020,432,733,796.11$21,639$1,527.95+$64916695.07MVNTA
7$2,226,904,004,397,647$2,157,443,140,649,837.00$25,057$1,903.80+$2226904004.37MVNTA
8$71,550,063,790,460,920$69,167,276,505,755,440.00$29,197$2,385.87+$71550063790.43MVNTA
9$2,153,505,628,518,013,700$2,076,947,060,262,220,500.00$34,250$3,008.70+$2153505628517.98MVNTA
10$60,726,414,423,802,585,000$58,422,163,401,288,310,000.00$40,467$3,819.61+$60726414423802.55MVNTA

VNTA vs EQR: Complete Analysis 2026

VNTAStock

Ventana Biotech, Inc., a development stage biotech company, identifies, evaluates, acquires, develops, and partners commercialization of intellectual property in the area of drug candidates for personalized medicine. The company focuses in the areas of anti-obesity and related illnesses. The company holds rights for the formula for a medicament containing chewing gum with a composition of the extract of hoodia gordonii and 2-hydroxyoleic acid for the treatment of obesity, hypertension, and other metabolic disorders. The company develops appetite suppressant chewing gums, including the low dosage product for the over-the-counter market and the high dosage product for distribution by pharmacists. It intends to market low dosage product though drug and health food stores. The company was formerly known as Personalica, Inc. and changed its name to Ventana Biotech, Inc. in October 2008. Ventana Biotech, Inc. was founded in 1989 and is based in Butschwil, Switzerland.

Full VNTA Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this VNTA vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VNTA vs SCHDVNTA vs JEPIVNTA vs OVNTA vs KOVNTA vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.